ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients

DOI Web Site Web Site PubMed 被引用文献2件 参考文献7件
  • Suzuki Shinya
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Otsuka Takayuki
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Sagara Koichi
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Semba Hiroaki
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Kano Hiroto
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Matsuno Shunsuke
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Takai Hideaki
    Department of Cardiovascular Surgery, The Cardiovascular Institute
  • Kato Yuko
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Uejima Tokuhisa
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Oikawa Yuji
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Nagashima Kazuyuki
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Kirigaya Hajime
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Kunihara Takashi
    Department of Cardiovascular Surgery, The Cardiovascular Institute
  • Yajima Junji
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Sawada Hitoshi
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Aizawa Tadanori
    Department of Cardiovascular Medicine, The Cardiovascular Institute
  • Yamashita Takeshi
    Department of Cardiovascular Medicine, The Cardiovascular Institute

この論文をさがす

抄録

Background:The association between ABO blood type and the activated partial thromboplastin time (aPTT) under dabigatran therapy in nonvalvular atrial fibrillation (NVAF) patients is unclear.Methods and Results:Between 2011 March and 2015 May, data on ABO blood type and aPTT under dabigatran were obtained for 396 NVAF patients (baseline aPTT, 166). The prevalence of blood type O tended to increase or significantly increase according to baseline aPTT, aPTT under dabigatran, and their difference (∆aPTT) (P=0.054, 0.001, and 0.012, respectively).Conclusions:In these NVAF patients, a high aPTT value under dabigatran therapy was associated with blood type O. (Circ J 2015; 79: 2274–2277)

収録刊行物

  • Circulation Journal

    Circulation Journal 79 (10), 2274-2277, 2015

    一般社団法人 日本循環器学会

被引用文献 (2)*注記

もっと見る

参考文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ